Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Planet-eating stars hint at Earth's ultimate fate - 2Explora Journeys becomes latest cruise line to be impacted by Middle East war
- 3Instructions to Pick the Right Gold Speculation Procedure: Exploring the Market
- 4How to watch the 2025 Macy's Thanksgiving Day Parade for free
- 5Meet ‘NASA Mike,’ who’s done 105,000 handstands around the world
- As tetanus vaccination rates decline, doctors worry about rising case numbers
- 5 Must-Attempt Fascinating Dishes from Around the World
- Ukraine's new defense minister just outlined how dire its troop shortage has become
- King Charles shares cancer treatment update, says it's a 'personal blessing'
- Track down Your Optimal Conservative Vehicle: Famous Brands to Consider
- Watch the Geminid meteor shower peak tonight from the comfort of home with this free livestream
- 6 Agreeable Earphones To Wear
- What’s the shadowy organisation taking Gaza Palestinians to South Africa?
- Germany's Lufthansa enters race for stake in Portuguese airline TAP
